Merck & Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE: SGP) today announced that they will complete their merger shortly after 4:00PM ET today. The companies will...
Interim results of Phase IIa NEXT-I study presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting BOSTON, Nov. 2 /PRNewswire-FirstCall/ -- Schering-Plough...
Program Focus: Community Education and Mass Vaccination of Dogs in 10 Villages KENILWORTH, N.J., Nov. 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today announced it has...
KENILWORTH, N.J., Nov. 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today announced that its investigational sublingual Grass (Phleum Pratense) Allergy Immunotherapy Tablet...
BOSTON, Nov. 1 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today reported two data presentations supporting response guided therapy with boceprevir combination therapy in...
KENILWORTH, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Schering-Plough Corp. (NYSE:SGP) announced today the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the...
CHICAGO, Oct. 30 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for CSCO, SGP, BHP, COST, and AEO. Seven Summits Strategic Investments' PriceWatch Alerts are available at...
NEW YORK, Oct. 29 /PRNewswire/ -- S&P 500 constituent Freeport -McMoRan Copper & Gold Inc. (NYSE:FCX) will replace Schering-Plough Corp. (NYSE:SGP) in the S&P 100, S&P MidCap 400 constituent...
Merck & Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE: SGP) today announced that they have received clearance from the U.S. Federal Trade Commission (FTC), the...
Merck & Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE: SGP) today announced that they have received clearance from the European Commission (EC) under the EC Merger...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales